亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Virological Failure on Long-Acting Injectable Cabotegravir and Rilpivirine: An Analysis of Subtypes, Drug Levels, Resistance, and Therapeutic Implications

医学 药品 整合酶 逆转录酶 抗药性 药理学 内科学 病毒学 逆转录酶抑制剂 整合酶抑制剂 病毒性疾病 人类免疫缺陷病毒(HIV) 药代动力学 梅德林 艾滋病毒耐药性 病毒 药物治疗 肿瘤科 免疫学 慢病毒 西达 化疗 外科
作者
Maria Mazzitelli,Miłosz Parczewski,David Marinus Burger,Annemarie M. J. Wensing
出处
期刊:Clinical Infectious Diseases [Oxford University Press]
卷期号:82 (6): 1023-1031 被引量:12
标识
DOI:10.1093/cid/ciag046
摘要

BACKGROUND: Virological failure (VF) with long-acting injectable cabotegravir and rilpivirine (CAB/RPV-LA) is uncommon but often associated with selection of resistance, potentially limiting future treatment options. Registration trials associated VF risk with baseline RPV resistance, A1/A6 subtypes, and body mass index (BMI) >30 kg/m2, but these factors have rarely been analyzed in other clinical settings. We summarize the first ∼100 reported VF cases, focusing on subtypes, drug levels, and resistance patterns. METHODS: Published data on CAB/RPV-LA through July 2025 were analyzed for risk factors. Resistance mutations were interpreted using the Stanford HIVdb database. RESULTS: After excluding duplicates, 94 VF cases were analyzed. Only 4.4% met the high-risk threshold of ≥2 risk factors. Subtype A lineages were reported in 26.4%, preexisting RPV mutations in 14.7%, and BMI >30 kg/m2 in 36.9%. At failure, low CAB or RPV levels were observed in 29% but did not differ from treatment successes. Predicted reduced susceptibility to CAB or RPV was observed in 87.2% (56% for both), with CAB resistance mutation N155H more frequently observed among subtype A lineages. Predicted susceptibility to dolutegravir/bictegravir (44.3%), doravirine (39.7%), or etravirine (35.9%) was common, but high-level resistance was rare. CONCLUSIONS: Emergent resistance in VF cases often resulted in cross-resistance to other nonnucleoside reverse transcriptase inhibitors and integrase strand transfer inhibitors. Although most cases did not meet the high-risk profile as defined by registration trials, subtype A lineages were overrepresented. Low drug levels were not elevated versus treatment successes. These data suggest that subtype-specific factors beyond A6 may influence VF risk and merit further study.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
威武青寒完成签到,获得积分10
11秒前
11完成签到 ,获得积分10
18秒前
28秒前
28秒前
34秒前
内向的紫槐完成签到,获得积分10
37秒前
39秒前
沉静问芙完成签到,获得积分10
43秒前
小黑桃完成签到,获得积分10
47秒前
jf完成签到 ,获得积分10
52秒前
57秒前
cc发布了新的文献求助10
1分钟前
科研通AI6.4的应助被祈愿采纳,获得10
1分钟前
qiao完成签到,获得积分10
1分钟前
Maestro_S的应助被cc采纳,获得10
1分钟前
1分钟前
jen完成签到 ,获得积分10
1分钟前
嘻嘻哈哈的应助被科研通管家采纳,获得10
1分钟前
斯文败类的应助被DRJ采纳,获得10
1分钟前
华仔的应助被科研通管家采纳,获得10
1分钟前
嘻嘻哈哈的应助被科研通管家采纳,获得10
1分钟前
嘻嘻哈哈的应助被科研通管家采纳,获得10
1分钟前
科目三的应助被科研通管家采纳,获得30
1分钟前
Ava的应助被科研通管家采纳,获得10
1分钟前
Isaac完成签到,获得积分10
1分钟前
SGD完成签到,获得积分10
1分钟前
corleeang完成签到 ,获得积分10
1分钟前
丰富夏菡完成签到,获得积分10
1分钟前
SGD发布了新的文献求助10
1分钟前
null的应助被Ella采纳,获得10
1分钟前
null的应助被Ella采纳,获得10
1分钟前
1分钟前
azhiyuan完成签到,获得积分10
1分钟前
搜集达人的应助被DRJ采纳,获得10
1分钟前
科研通AI6.4的应助被SUNny采纳,获得10
1分钟前
九灶完成签到 ,获得积分10
1分钟前
null的应助被Ella采纳,获得10
1分钟前
1分钟前
null的应助被Ella采纳,获得10
1分钟前
小黑桃发布了新的文献求助10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Hidden Empire of Finance: How Wall Street Profits from Our Cities and Fuels Global Inequality 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8165939
求助须知:如何正确求助?哪些是违规求助? 9559318
关于积分的说明 21749898
捐赠科研通 7756692
什么是DOI,文献DOI怎么找? 3429083
关于科研通互助平台的介绍 2553385
邀请新用户注册赠送积分活动 2473623